Citi raises Novo Nordisk stock target despite ’mixed’ results
Citi increased its price target for Novo Nordisk to DKK298 from DKK296, maintaining a neutral rating. The bank called the company's Q3 results mixed, with adjusted sales and operating income guidance suggesting a 3% consensus upgrade for 2026. Citi raised its estimates by 3% to 5% due to Wegovy Pill IO sales but lowered outer-year estimates by up to 6% due to competition from Eli Lilly's retatrutide. Novo Nordisk did not commit to 2027 growth, citing uncertainty.
How this was made
The 30-second read
Why it matters
The price‑target increase reflects confidence in short‑term growth while highlighting long‑term uncertainty.
Market read
Analyst target raise may prompt short‑term buying interest in NVO, with broader implications for the pharma sector.
What to watch
Potential competitive pressure from Eli Lilly's retatrutide and uncertain pricing beyond 2027 may limit upside.
Background
Citi analysts reviewed Novo Nordisk's Q3 results, noting mixed performance but strong Wegovy Pill IO sales.
Ticker impact
Citi raised Novo Nordisk's price target to DKK298 from DKK296 and kept a neutral rating.
slight upward pressure as investors price in the higher target
Citi's target raise reflects optimism on Wegovy Pill IO sales, but uncertainty beyond 2027 tempers the view.
Market effects
The target raise may lift other diabetes/obesity drug makers as the sector gains attention.
European pharma stocks could see modest gains from the positive outlook on Novo Nordisk.
Limited to investors tracking major pharma and obesity‑treatment markets.
Counterpoint
Citi's cautious neutral rating and noted visibility issues for 2027 could signal overvaluation risk.
Key entities
- companyNovo Nordisk
Danish pharmaceutical firm focused on diabetes and obesity treatments.
- analystCiti
Investment bank providing the price‑target revision.
